Risk prediction model construction for asthma after allergic rhinitis by blood immune T effector cells

Jian Wang,Tao Jiang,Jian-Dao Hu
DOI: https://doi.org/10.1097/md.0000000000037287
IF: 1.6
2024-02-25
Medicine
Abstract:Asthma (AS) and rhinitis are common airway diseases worldwide. AS is a persistent inflammatory condition marked by reversible airway blockage and heightened reactivity, often triggered by allergies or infections. [ 1 , 2 ] Repeated episodes of bronchiolitis can directly affect a patient's lung function and exacerbate the patient's airway inflammatory response. As an upper respiratory allergic disease, allergic rhinitis (AR) is often co-morbid with bronchial asthma, and can aggravate the symptoms of bronchial asthma and promote its progression. [ 3 , 4 ] Asthma's prevalence varies worldwide, ranging from 1% to 18%, with the highest rates observed in Western countries. [ 5 ] AR affects 10% to 20% of the population in Europe and the US. [ 6–9 ] The incidence of bronchiolitis combined with AR ranges from 60% to 90%. AR not only aggravates bronchiolar wheezing, but also affects the efficacy of wheezing treatment. At present, there are few researches on the biological markers of AR to AS progression.
medicine, general & internal
What problem does this paper attempt to address?